Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Feb 15;2012(2):CD000124.
doi: 10.1002/14651858.CD000124.pub2.

Lobeline for smoking cessation

Lindsay F Stead  1 , John R Hughes
Affiliations

Lobeline for smoking cessation

Lindsay F Stead et al. Cochrane Database Syst Rev. .

Abstract

Background: Lobeline is a partial nicotine agonist, which has been used in a variety of commercially available preparations to help stop smoking.

Objectives: The objective of this review was to assess the effects of lobeline on long term smoking cessation.

Search methods: We searched the Cochrane Tobacco Addiction Group trials register (most recent search December 2011).

Selection criteria: Randomized trials comparing lobeline to placebo or an alternative therapeutic control, which reported smoking cessation with at least six months follow-up.

Data collection and analysis: We extracted data in duplicate on the type of subjects, the dose and form of lobeline, the outcome measures, method of randomisation, and completeness of follow-up.

Main results: We identified no trials meeting the full inclusion criteria including long term follow-up. One large trial failed to detect any effect on short-term abstinence.

Authors' conclusions: There is no evidence available from long term trials that lobeline can aid smoking cessation, and the short-term evidence suggests there is no benefit.

PubMed Disclaimer

Conflict of interest statement

JH has received consulting fees from several for‐profit and nonprofit organizations that provide smoking cessation medications and services.

Update of

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

References to studies excluded from this review

Bachman 1964 {published data only}
    1. Bachman DS. Group smoking deterrent therapy. GP 1964;30:86. - PubMed
Bartlett 1957 {published data only}
    1. Bartlett WA, Whitehead RW. The effectiveness of meprobamate and lobeline as smoking deterrents. Journal of Laboratory and Clinical Medicine 1957;50(2):278‐81. - PubMed
BTA 1963 {published data only}
    1. British Tuberculosis Association Research Committee. Smoking deterrent study. British Medical Journal 1963;2:486‐7. - PMC - PubMed
Davison 1972 {published data only}
    1. Davison GC, Rosen RC. Lobeline and reduction of cigarette smoking. Psychological Reports 1972;31:443‐56. - PubMed
Dorsey 1936 {published data only}
    1. Dorsey JL. Control of the tobacco habit. Annals of Internal Medicine 1936;10:628‐31.
Edwards 1964 A {published data only}
    1. Edwards G. Double‐Blind Trial of Lobeline in an Anti‐Smoking Clinic. Medical Officer 1964;112:158‐60.
Edwards 1964 B {published data only}
    1. Edwards G. Hypnosis and lobeline in an Anti‐Smoking Clinic. Medical Officer 1964;111:239‐43.
Ejrup 1959 {published data only}
    1. Ejrup B. Follow‐up of the material of smokers difficult to treat. Svenska Läkartidningen 1959;56:2254‐62. - PubMed
    1. Ejrup B. Fortsatta forsok till avvanjing fran toback medelst injektions behandling. Svenska Läkartidningen 1959;56:1975‐86. - PubMed
Ejrup 1967 {published data only}
    1. Ejrup B. Report to American Cancer Society Conference of Experts on Ways to help people give up smoking. New York City. 19‐20 Dec 1967.
Farago 1968 {published data only}
    1. Farago I. Results of a weaning cure of 1125 smokers. Contribution to the nicotine addiction problem [Ergebnisse der entwohnungskuren von 1125 rauchern:beitrag zum nikotinsucht‐problem]. Schweizer Archiv fur Neurologie Neurochirurgie und Psychiatrie 1968;102:167‐89. - PubMed
Glover 1998 {published data only}
    1. Glover ED, Leischow SJ, Rennard SI, Glover PN, Daughton D, Quiring JN, et al. A smoking cessation trial with lobeline sulfate: A pilot study. American Journal of Health Behavior 1998;22:62‐74.
    1. Schneider FH, Olsson TA. Clinical experience with lobeline as a smoking cessation agent. Medicinal Chemistry Research 1996;6:562‐70.
Glover 2010 {published data only}
    1. DynaGen Inc. NicErase‐SL multi‐center phase 3 trial shows efficacy in one of three sites. Press Release 29 August 1997.
    1. Glover ED, Rath JM, Sharma E, Glover PN, Laflin M, Tonnesen P, et al. A multicenter phase 3 trial of lobeline sulfate for smoking cessation. American Journal of Health Behavior 2010;34:101‐9. - PubMed
Golledge 1965 {published data only}
    1. Golledge AH. Influencing factors in ant‐smoking clinics together with the results of a double blind trial of Lobidan. Medical Officer 1965;114:59‐61.
Graff 1966 {published data only}
    1. Graff H, Hammet VO, Bash N, Fackler G, Yanovski A, Goldman A. Results of four antismoking methods. Pennsylvania Medical Journal 1966;69:86‐9. - PubMed
Hoffstaedt 1964 {published data only}
    1. Hoffstaedt EGW, Pearson RCM. The experimental smokers' advisory clinic Newcastle upon Tyne. Medical Officer 1964;111(31 Jan):59‐60.
Hoffstaedt 1965 {published data only}
    1. Hoffstaedt EGW. The treatment of the unwilling smoker. A clinical approach. Practitioner 1965;195:794‐8. - PubMed
Jacobs 1971 {published data only}
    1. Jacobs MA, Spilken AZ, Norman MM, Wohlberg GW, Knapp PH. Interaction of personality and treatment conditions associated with success in a smoking control program. Psychosomatic Medicine 1971;33:545‐56. - PubMed
Jochum 1961 {published data only}
    1. Jochum K, Jost F. Nicotine addiction and its treatment. Münchener Medizinische Wochenschrift 1961;103:618‐22. - PubMed
Kalyuzhny 1968 {published data only}
    1. Kalyuzhny VV. The treatment of tobacco smoking by means of lobeline and the effect of lobeline on vegetative and vascular reactions. Zh Nevropatol Psikhiatr 1968;68:1864‐70. - PubMed
Kaufman 1960 {published data only}
    1. Kaufman H, Bensimon L. Tobacco withdrawal [Le sevrage du tabac]. Vie Medicale 1960;41:1139. - PubMed
Leone 1968 {published data only}
    1. Leone LA, Musiker HR, Albala MM, McGurk W. A study of the effectiveness of the smoking deterrence clinic. Rhode Island Medical Journal 1968;51:247‐257,260. - PubMed
London 1963 {published data only}
    1. London SJ. Clinical evaluation of a new lobeline smoking deterrent. Current Therapeutic Research 1963;5(4):167‐75.
McChargue 2002 {published data only}
    1. McChargue DE, Collins FL, Cohen LM. Effect of non‐nicotinic moist snuff replacement and lobeline on withdrawal symptoms during 48‐h smokeless tobacco deprivation. Nicotine & Tobacco Research 2002;4(2):195‐200. - PubMed
Merry 1963 {published data only}
    1. Merry J, Preston G. The effect of buffered lobeline sulphate on cigarette smoking. Practitioner 1963;190:628‐31. - PubMed
Perlstein 1964 {published data only}
    1. Perlstein IB. Smoking deterrent therapy in private practice. The first M.R. Thompson Symposium on recent advances in the medical aspects of smoking. New York: Matthew Publishing Co, 1964:40‐5.
Rapp 1955 {published data only}
    1. Rapp GW, Olen AA. A critical evaluation of a lobeline based smoking deterrent. American Journal of Medical Science 1955;230:9‐14. - PubMed
Rapp 1959 {published data only}
    1. Rapp GW, Dusza BT, Blanchet L. Absorption and utility of lobeline as a smoking deterrent. American Journal of Medical Science 1959;237:287‐92. - PubMed
Rosenberg 1959 {published data only}
    1. Rosenberg A. Attempt at stopping the tobacco habit. Ugeskrift for Laeger 1959;121:881‐6. - PubMed
Rosnick 1965 {published data only}
    1. Rosnick MJ. The smoking deterrent effect of a new lobeline dosage form. Journal of the Florida Medical Association 1965;52:27‐30. - PubMed
Ross 1967 {published data only}
    1. Ross CA. Smoking withdrawal research clinics. American Journal of Public Health 1967;57:677‐81. - PMC - PubMed
Schneider 1996a {published data only}
    1. Schneider FH, Olsson TA. Clinical experience with lobeline as a smoking cessation agent. Medicinal Chemistry Research 1996;6:562‐70.
Schneider 1996b {published data only}
    1. Schneider FH, Mione PJ, Raheman FS, Phillips BM, Quiring JN. Reduction of tobacco withdrawal symptoms by sublingual lobeline sulfate. American Journal of Health Behavior 1996;20:346‐63.
Scott 1962 {published data only}
    1. Scott GW, Cox AGC, MacLean KS, Price TML, Southwell N. Buffered lobeline as a smoking deterrent. Lancet 1962;279(7219):54‐5.
Swartz 1964 {published data only}
    1. Swartz H, Cohen A. Clinical evaluation of SmoKurb as a smoking deterrent. Current Therapeutic Research 1964;6(4):290‐6. - PubMed
Wright 1937 {published data only}
    1. Wright IS, Littauer D. Lobeline sulphate: its pharmacology and use in the treatment of the tobacco habit. JAMA 1937;109:649‐654.

Additional references

Cahill 2011
    1. Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database of Systematic Reviews. Cochrane Database of Systematic Reviews 2011, Issue 2. [DOI: 10.1002/14651858.CD006103.pub5] - DOI - PubMed
FDA 1993
    1. Department of Health and Human Services, Food, Drug Administration. Smoking deterrent drug products for Over‐the‐Counter human use. FR 31236 1 June 1993; Vol. 58, issue 103.
Schwartz 1969
    1. Schwartz JL. A critical review and evaluation of smoking control methods. Public Health Reports 1969;84:483‐506. - PMC - PubMed
Stead 2008
    1. Stead LF, Perera R, Bullen C, Mant D, Lancaster T. Nicotine replacement therapy for smoking cessation. Cochrane Database of Systematic Reviews 2008, Issue 1. [DOI: 10.1002/14651858.CD000146.pub3] - DOI - PubMed
West 2011
    1. West R, Zatonski W, Cedzynska M, Lewandowska D, Pazik J, Aveyard P, et al. Placebo‐controlled trial of cytisine for smoking cessation. 2011. New England Journal of Medicine 2011;365:1193‐1200. - PubMed
Yusuf 1985
    1. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Progress in Cardiovascular Disease 1985;27(5):335‐71. - PubMed

Publication types